Stocks of BioNTech SE (NASDAQ:BNTX) traded higher last session on Wall Street, down -1.23% to $127.29.
As we calculate the median target price by taking the range between a high of $276.74 and a low of $132.80, we find $187.16. Given the previous closing price of $128.88, this indicates a potential upside of 45.22 percent. BNTX stock price is now -10.66% away from the 50-day moving average and -14.91% away from the 200-day moving average. The market capitalization of the company currently stands at $30.23B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Brokers who have rated the stock have averaged $189.30 as their price target over the next twelve months.
With the price target maintained at $239, BofA Securities recently Upgraded its rating from Neutral to Buy for BioNTech SE (NASDAQ: BNTX). On August 17, 2022, Cowen recently initiated its ‘Market Perform’ rating on the stock quoting a target price of $177, while ‘SVB Leerink’ rates the stock as ‘Outperform’.
A total of 64.01% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BNTX stock. A new stake in BioNTech SE shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $42,195,000. AVIDITY PARTNERS MANAGEMENT LP invested $27,418,000 in shares of BNTX during the first quarter. In the first quarter, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP acquired a new stake in BioNTech SE valued at approximately $21,875,000. FARALLON CAPITAL MANAGEMENT LLC acquired a new stake in BNTX for approximately $17,821,000. GRATUS CAPITAL LLC purchased a new stake in BNTX valued at around $10,275,000 in the second quarter. In total, there are 494 active investors with 17.00% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $128.99 for BioNTech SE (NASDAQ: BNTX). During the past 12 months, BioNTech SE has had a low of $117.08 and a high of $188.99. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 5.40, and a quick ratio of 5.30. The fifty day moving average price for BNTX is $142.48 and a two-hundred day moving average price translates $149.68 for the stock.
The latest earnings results from BioNTech SE (NASDAQ: BNTX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at $7.44, beating analysts’ expectations of $4.8 by 2.64. This compares to $14.56 EPS in the same period last year. The net profit margin was 55.60% and return on equity was 65.50% for BNTX. The company reported revenue of $3.49 billion for the quarter, compared to $7.18 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -51.43 percent. For the current quarter, analysts expect BNTX to generate $4.48B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/17/2022. Investors who held shares on 06/03/2022 were paid a $2.111 dividend.
BioNTech SE(BNTX) Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
